Literature DB >> 19560086

Echocardiographic study of the optimal atrioventricular delay at rest and during exercise in recipients of cardiac resynchronization therapy systems.

Bilel Mokrani1, Stephane Lafitte, Antoine Deplagne, Sylvain Ploux, Julien Laborderie, Patricia Reant, Pierre Dos Santos, Raymond Roudaut, Pierre Jais, Michel Haissaguerre, Jacques Clementy, Pierre Bordachar.   

Abstract

BACKGROUND: It is unclear whether, in recipients of cardiac resynchronization therapy (CRT) systems, the optimal AV delay should be the same, shorter, or longer during exercise than at rest.
OBJECTIVE: This study sought to examine the effects of atrioventricular (AV) delay optimization at rest and during exercise in 50 recipients of CRT systems.
METHODS: We measured left ventricular (LV) outflow tract velocity time integral (OT-VTI) and LV filling time (FT) echocardiographically, at rest and during exercise to 60% of the maximal predicted heart rate, with the sensed AV delay set at 40, 70, 100, 120, 150, and 200 ms. The measurements made at rest versus those made during exercise, and among the several programmed AV delays, were compared.
RESULTS: The optimal AV delay based on LVOT-VTI was shorter during exercise than at rest in 37%, unchanged in 37%, and longer in 26% of patients. The optimal AV delay based on LVFT was shorter during exercise than at rest in 27%, unchanged in 23%, and longer in 50% of patients. Optimization of the AV delay during exercise increased LVFT and LVOT-VTI significantly (P < .05) compared with (1) any other arbitrarily chosen AV delay, (2) the optimal AV delay at rest, (3) an AV delay systematically shortened from rest to exercise.
CONCLUSION: Optimization of the AV delay had a positive effect on echocardiographic indices of LV function. The systematic shortening of the AV delay during exercise is not recommended because, in a high proportion of patients, the optimal AV delay was longer during exercise than at rest.

Entities:  

Mesh:

Year:  2009        PMID: 19560086     DOI: 10.1016/j.hrthm.2009.03.023

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  6 in total

1.  AV interval optimization using pressure volume loops in dual chamber pacemaker patients with maintained systolic left ventricular function.

Authors:  Frank Eberhardt; Thorsten Hanke; Joern Fitschen; Matthias Heringlake; Frank Bode; Heribert Schunkert; Uwe K H Wiegand
Journal:  Clin Res Cardiol       Date:  2012-03-09       Impact factor: 5.460

2.  Left univentricular pacing for cardiac resynchronization therapy using rate-adaptive atrioventricular delay.

Authors:  Li-Jin Pu; Yu Wang; Lu-Lu Zhao; Tao Guo; Shu-Min Li; Bao-Tong Hua; Ping Yang; Jun Yang; Yan-Zhou Lu; Liu-Qing Yang; Ling Zhao; Hai-Yun Luo
Journal:  J Geriatr Cardiol       Date:  2017-02       Impact factor: 3.327

3.  Optimisation of cardiac resynchronization therapy in clinical practice during exercise.

Authors:  M M D Molenaar; B Oude Velthuis; M F Scholten; J Y Stevenhagen; W A Wesselink; J M van Opstal
Journal:  Neth Heart J       Date:  2013-10       Impact factor: 2.380

Review 4.  Atrioventricular and interventricular delay optimization in cardiac resynchronization therapy: physiological principles and overview of available methods.

Authors:  Patrick Houthuizen; Frank A L E Bracke; Berry M van Gelder
Journal:  Heart Fail Rev       Date:  2011-05       Impact factor: 4.214

5.  Shortening of atrioventricular delay at increased atrial paced heart rates improves diastolic filling and functional class in patients with biventricular pacing.

Authors:  Reza Rafie; Salima Qamruddin; Ali Ozhand; Nima Taha; Tasneem Z Naqvi
Journal:  Cardiovasc Ultrasound       Date:  2012-01-24       Impact factor: 2.062

6.  Frequency and causes of QRS prolongation during exercise electrocardiogram testing in biventricular paced patients with heart failure.

Authors:  Brett D Atwater; Kasper Emerek; Zak Loring; Christoffer Polcwiartek; Kevin P Jackson; Daniel J Friedman
Journal:  HeartRhythm Case Rep       Date:  2020-05-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.